Target: Glycogen synthase kinase-3 (GSK-3α and GSK-3β)
Approach: Inhibit GSK-3 activity to reduce tau hyperphosphorylation, amyloid production, and neuroinflammation
Therapeutic Area: Alzheimer's Disease, Parkinson's Disease, ALS, FTD, Bipolar Disorder
Score: 78/100
Glycogen synthase kinase-3 (GSK-3) is a serine/threonine kinase with two isoforms: GSK-3α and GSK-3β. It is one of the most actively studied drug targets in neurodegeneration due to its involvement in multiple pathogenic processes.
Key GSK-3 substrates:
GSK-3 is hyperactive in Alzheimer's disease and other neurodegenerative conditions:
Alzheimer's Disease:
- GSK-3β activity elevated in AD hippocampus
- Drives tau hyperphosphorylation and NFT formation
- Increases amyloid-β production through APP processing
- Impairs synaptic plasticity and memory
- Active in neuroinflammation through NF-κB activation
Parkinson's Disease:
- GSK-3 promotes α-synuclein phosphorylation (Ser129)
- Contributes to dopaminergic neuron death
- Links to mitochondrial dysfunction
ALS:
- TDP-43 phosphorylation by GSK-3
- Motor neuron vulnerability
Several GSK-3 inhibitor classes are in development:
- ATP-competitive inhibitors: Tideglusib, CHIR99021, SB-216763
- Non-ATP-competitive: VP0.7
- Natural products: Lithium, curcumin derivatives
- Novel agents: AZD1080, PF-04802367
Lithium remains the best-studied GSK-3 inhibitor but has dose-limiting side effects.
| Dimension |
Score |
Rationale |
| Novelty |
7 |
Well-studied target; several inhibitors in trials |
| Mechanistic Rationale |
9 |
Strong genetic and biochemical validation |
| Root-Cause Coverage |
8 |
Addresses tau pathology, amyloid, neuroinflammation |
| Delivery Feasibility |
6 |
Brain penetration challenging for many inhibitors |
| Safety Plausibility |
6 |
Off-target effects, narrow therapeutic window |
| Combinability |
8 |
Works with anti-amyloid, autophagy enhancers |
| Biomarker Availability |
8 |
p-tau levels, kinase activity assays |
| De-risking Path |
7 |
Some inhibitors have clinical history |
| Multi-disease Potential |
9 |
High across AD, PD, ALS, FTD, BD |
| Patient Impact |
8 |
Large disease-modifying potential |
Total: 78/100
Tideglusib (NP031112):
- Phase 2 trial in AD: Primary endpoints not met
- Some cognitive benefit observed in apolipoprotein E4 carriers
- Generally well-tolerated
Lithium:
- Mixed results in AD and PD trials
- Low-dose lithium may have neuroprotective effects
- Safety concerns at higher doses
- Novel GSK-3 inhibitors in preclinical development
- Combination approaches with other mechanisms
- Therapeutic window: Achieving brain penetration without peripheral toxicity
- Isoform selectivity: Targeting β isoform while sparing α
- Chronic dosing: Long-term treatment required
- Biomarker validation: Need robust p-tau lowering markers
GSK-3 inhibitors synergize with:
- Anti-amyloid antibodies (reduces amyloid-driven GSK-3 activation)
- Autophagy inducers (complementary protein clearance)
- Tau immunotherapy (different mechanism)
- Metabolic modulators (NAD+, GLP-1)
- Isoform-selective inhibitor screening: Screen novel GSK-3β-selective inhibitors for brain penetration, prioritizing compounds with >50-fold selectivity over GSK-3α. Use in vitro kinase assays with tau phosphorylation (Ser396) as readout.
- Patient-derived neuron testing: Test lead compounds in iPSC-derived neurons from AD and PD patients. Measure p-tau (Thr231, Ser396), total tau, and amyloid secretion.
- Combination synergy studies: Test GSK-3 inhibitors in combination with anti-amyloid antibodies (lecanemab, donanemab), autophagy inducers (TFEB activators), or NAD+ boosters to identify synergistic combinations.
- Patient enrichment strategy: Select patients with elevated baseline p-tau217 or p-tau181 in CSF or plasma. Target early-stage AD (MCI due to AD or mild AD dementia).
- Dose-finding design: Use staggered low-dose escalation to find optimal brain exposure. Primary endpoint: CSF p-tau reduction at 6 months. Secondary: amyloid PET, cognitive measures.
- Biomarker monitoring: Establish p-tau and total tau in CSF as pharmacodynamic markers. Consider tau PET as secondary endpoint.
- AstraZeneca/GSK partnership: AZD1080 was discontinued - position novel approach as next-generation with improved brain penetration and selectivity.
- Tideglusib (Noscira): Their compound failed - learn from their dosing and formulation experience.
- Academic networks: Partner with Alzheimer's Clinical Trial Consortium (ACTC) for trial design and execution.
- Screen novel GSK-3β-selective inhibitors with CLogP < 3, PSA < 80
- Optimize for brain penetration and kinase selectivity
- Begin SAR studies for tau phosphorylation inhibition
- Budget: $2-4M
- GLP toxicology in rat and cynomolgus monkey (6-month)
- CMC development for oral and/or subcutaneous formulation
- Biomarker assay development (p-tau in CSF, plasma)
- IND package preparation
- Budget: $5-8M
- Phase 1 safety in healthy volunteers (completed)
- Phase 2 dose-finding in early AD patients
- Phase 2b registration-enabling trial
- Budget: $20-35M
- Phase 3 registration trials in early AD
- NDA/MAA submission
- Budget: $60-100M
Total Program Cost: $87-147M over 96 months (8 years)
| Institution |
Key Investigators |
Relevance |
| UCL Queen Square |
Dr. John Hardy |
GSK-3 biology in AD |
| Mayo Clinic Jacksonville |
Dr. Leonard Petrucelli |
Tau biology, therapeutic targeting |
| UC San Diego |
Dr. Paula Desplats |
Neurodegeneration, GSK-3 |
| Banner Sun Health |
Dr. Thomas Beach |
Human brain tissue, biomarker validation |
| Company |
Relevance |
| Noscira (Tideglusib) |
Failed Phase 2 - learn from experience |
| Lilly |
Amyloid antibody combinations |
| Biogen |
Tau programs, CNS delivery |
¶ Milestones and Go/No-Go Decision Points
-
Lead Selection (Month 15)
- Go: >100-fold GSK-3β selectivity, brain:plasma >0.3, >50% p-tau reduction in vitro
- No-Go: Insufficient selectivity or brain penetration
-
IND-Enabling Toxicology (Month 30)
- Go: NOAEL established in two species, no tumorigenic signals
- No-Go: Unexpected toxicity requiring reformulation
-
Phase 2b Efficacy (Month 60)
- Go: >20% slowing of clinical decline (CDR-SB), significant p-tau reduction
- No-Go: Insufficient efficacy - pivot to combination therapy or prevention
¶ Risks and Mitigations
| Risk |
Mitigation |
| Tumorigenesis risk (β-catenin) |
Use isoform-selective inhibitors |
| Peripheral toxicity |
Optimize brain penetration |
| Narrow therapeutic window |
Careful dose titration |
| Wnt pathway disruption |
Monitor GI effects |